Pipeline
EU307
| Indication GPC3 expressing cancer | Target /Drug class GPC3 expressing cancer cell / CAR-T | Development Stage Non-clinical |
Summary
- 4th generation GPC3 CAR-T shows better efficacy compared to 2nd generation GPC3 CAR-T
- Shows better efficacy for tumor clearance than 2nd generation GPC3 CAR-T in vivo
- Clear anti-cancer efficacy in an orthotopic model
- Smaller number of 4th generation GPC3 CAR-T required than other groups to remove HCC
